Moderna weekly uptrend opportunity based On 1.00 Lot Calculation:
- Moderna, Inc. a clinical-stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
- EVENT: Moderna Inc said on Saturday it has agreed to supply the Philippines government with 13 million doses of its COVID-19 vaccine, with deliveries set to begin in mid-2021. The company will work with regulators to pursue necessary approvals before distribution, it said in a press release.
- EVENT: Moderna announced that its partner in Japan, Takeda Pharmaceutical, submitted a New Drug Application (NDA) for its now-famous mRNA-1273 coronavirus vaccine (known as TAK-919 in that nation).
In a potentially positive development, a study conducted at California's La Jolla Institute for Immunology seems to indicate that the T cells produced by mRNA-1273 are efficacious against the four currently most concerning variants of the coronavirus. The news was generally good for the Moderna, particularly the Japan New Drug Application (even if it was more or less expected).
EVENT: Moderna Inc said on Saturday it has agreed to supply the Philippines government with 13 million doses of its COVID-19 vaccine, with deliveries set to begin in mid-2021. The company will work with regulators to pursue necessary approvals before distribution, it said in a press release. - Moderna is on track to make 700 million doses of its coronavirus vaccine this year, Moderna CEO Stephane Bancel said. The company is now adding staff with the hopes of reaching 1 billion doses this year and up to 1.4 billion doses in 2022. In 2021, we are continuing to scale our commercial network. We plan to open commercial subsidiaries this year in Japan, South Korea, and Australia. I look forward to planting the Moderna flag in Tokyo, Seoul, and Sydney, Bancel predicted.
- Moderna closed the year with eight commercial subsidiaries, an incredible commercial team, and commercial partners and now have commercial operations in the U.S.; in Canada; in Europe, in the five largest markets: Germany, France, Italy, Spain, and the U.K. They established one in Switzerland, where they have both commercial capabilities to serve the Swiss market, as well as manufacturing for geographies outside the U.S. with partner Lonza. Moderna have partnered with Medison in Israel and with Takeda in Japan.
Moderna, March 8, 2021
Current Price: 132
|
Moderna |
Weekly |
|
Trend direction |
|
|
170 |
|
|
158 |
|
|
145 |
|
|
120 |
|
|
106 |
|
|
95 |
Example of calculation based on weekly trend direction for 1.00 Lot*
|
Moderna |
||||||
|
Pivot Points |
||||||
|
Profit or loss in $ |
38,000 |
26,000 |
13,000 |
-12,000 |
-26,000 |
-37,000 |
|
Profit or loss in €* |
31,949 |
21,860 |
10,930 |
-10,089 |
-21,860 |
-31,108 |
|
Profit or loss in £** |
27,461 |
18,789 |
9,394 |
-8,672 |
-18,789 |
-26,738 |
|
Profit or loss in C$** |
48,165 |
32,955 |
16,478 |
-15,210 |
-32,955 |
-46,898 |
* 1.00 lot is equivalent of 1000 units
** Calculations for exchange rate used as of 09:00 am GMT 8/03/2021
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Client Manager regarding their use.
*** You may wish to consider closing your position in profit, even if it is lower than suggested one
**** Trailing stop technique can protect the profit – Ask your Client Manager for more detail